Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 205 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: levonorgestrel Clear all

Conditions: Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
Interventions: Tirzepatide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Healthy Participants
Interventions: Elenestinib, Midazolam, Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG); Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: HIV
Interventions: no intervention; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Contraception
Interventions: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2, levonorgestrel patch with BMI <32 kg/m2; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Aurora, Colorado • New York, New York • Cincinnati, Ohio + 3 more

Conditions: Healthy
Interventions: AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
Interventions: Norethindrone acetate pretreatment, No pretreatment; Drug · Other
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healthy
Interventions: Levonorgestrel-releasing intrauterine system (LNG-IUS); Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epithelial Ovarian Cancer
Interventions: Mirena® intra-uterine device (IUD); Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Endometrial Bleeding, Periodontal Disease
Interventions: doxycycline; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Birth Control
Interventions: Not listed
Lead sponsor: Valleywise Health; Other
Eligibility: 25 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Phoenix, Arizona • Scottsdale, Arizona

Conditions: Hot Flashes
Interventions: Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 45
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more

Conditions: Contraception, Bleeding
Interventions: transdermal estradiol, naproxen, oral placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Contraception
Interventions: Placebo Control (Placebo Herb), St. John's Wort, Levonorgestrel; Dietary Supplement · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions: Levonorgestrel intrauterine system, Combined oral contraceptives; Device · Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Inflammatory Bowel Diseases, Contraception, Menstrual Problem
Interventions: Proposed study design and randomization scenarios, Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments, Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Estrogen Therapy
Interventions: Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy; Drug · Device
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 456,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Eden Prairie, Minnesota

Conditions: Menopausal and Other Perimenopausal Disorders
Interventions: Mirena, Estradiol, Placebo Gel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 52 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Bariatric Surgery Candidate, Contraception
Interventions: ethinyl estradiol-levonorgestrel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pregnancy
Interventions: Mirena (Levonorgestrel IUS, BAY86-5028), ParaGard, Implanon/Nexplanon; Drug
Lead sponsor: Bayer; Industry
Eligibility: 15 Years to 44 Years · Female only
Enrollment: 13,880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Temporomandibular Joint Disorders
Interventions: Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions: Mirena, Oral contraception, Depo-Provera; Drug
Lead sponsor: Thomas Cherpes, DVM, MD; Other
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer

A Study of Elenestinib in Healthy Adult Female Participants

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

AZD6140 Oral Contraceptive Interaction Study

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion

Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation

Norplant and Irregular Bleeding/Spotting

The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel

Stopping Heavy Periods Project

Hormonal Influences on Inflammatory Bowel Diseases

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

Duration of Use of Highly Effective Reversible Contraception

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Managing Temporomandibular Disorder (TMD) Symptoms

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives